JP2024544013A5 - - Google Patents

Info

Publication number
JP2024544013A5
JP2024544013A5 JP2024533014A JP2024533014A JP2024544013A5 JP 2024544013 A5 JP2024544013 A5 JP 2024544013A5 JP 2024533014 A JP2024533014 A JP 2024533014A JP 2024533014 A JP2024533014 A JP 2024533014A JP 2024544013 A5 JP2024544013 A5 JP 2024544013A5
Authority
JP
Japan
Prior art keywords
protein
lipid
fusion protein
plasma membrane
therapeutic cargo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024533014A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024544013A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/080856 external-priority patent/WO2023102550A2/en
Publication of JP2024544013A publication Critical patent/JP2024544013A/ja
Publication of JP2024544013A5 publication Critical patent/JP2024544013A5/ja
Pending legal-status Critical Current

Links

JP2024533014A 2021-12-03 2022-12-02 有効なin vivo送達のための組成物および方法 Pending JP2024544013A (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US202163285995P 2021-12-03 2021-12-03
US63/285,995 2021-12-03
US202263298626P 2022-01-11 2022-01-11
US202263298621P 2022-01-11 2022-01-11
US202263298611P 2022-01-11 2022-01-11
US63/298,621 2022-01-11
US63/298,611 2022-01-11
US63/298,626 2022-01-11
US202263423372P 2022-11-07 2022-11-07
US63/423,372 2022-11-07
PCT/US2022/080856 WO2023102550A2 (en) 2021-12-03 2022-12-02 Compositions and methods for efficient in vivo delivery

Publications (2)

Publication Number Publication Date
JP2024544013A JP2024544013A (ja) 2024-11-26
JP2024544013A5 true JP2024544013A5 (enExample) 2025-12-04

Family

ID=85172989

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024533014A Pending JP2024544013A (ja) 2021-12-03 2022-12-02 有効なin vivo送達のための組成物および方法

Country Status (9)

Country Link
US (3) US20250223584A2 (enExample)
EP (1) EP4441074A2 (enExample)
JP (1) JP2024544013A (enExample)
KR (1) KR20240130158A (enExample)
AU (1) AU2022402249A1 (enExample)
CA (1) CA3239381A1 (enExample)
GB (1) GB2631171A (enExample)
IL (1) IL313161A (enExample)
WO (1) WO2023102550A2 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9340799B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College MRNA-sensing switchable gRNAs
US9388430B2 (en) 2013-09-06 2016-07-12 President And Fellows Of Harvard College Cas9-recombinase fusion proteins and uses thereof
US11898179B2 (en) 2017-03-09 2024-02-13 President And Fellows Of Harvard College Suppression of pain by gene editing
EP3592381A1 (en) 2017-03-09 2020-01-15 President and Fellows of Harvard College Cancer vaccine
EP3820495A4 (en) 2018-07-09 2022-07-20 The Broad Institute Inc. RNA-PROGRAMMABLE EPIGENETIC RNA MODIFIERS AND THEIR USES
EP3942043A2 (en) 2019-03-19 2022-01-26 The Broad Institute, Inc. Methods and compositions for editing nucleotide sequences
WO2020214842A1 (en) 2019-04-17 2020-10-22 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
CN114258398A (zh) 2019-06-13 2022-03-29 总医院公司 工程化的人内源性病毒样颗粒及使用其递送至细胞的方法
CN116670154A (zh) 2020-07-24 2023-08-29 总医院公司 增强的病毒样颗粒及使用其递送至细胞的方法
US12565647B2 (en) 2021-05-28 2026-03-03 The Regents Of The University Of California Compositions and methods for targeted delivery of CRISPR-Cas effector polypeptides and transgenes
CN120303407A (zh) * 2022-05-17 2025-07-11 恩维洛普治疗有限责任公司 用于有效体内递送的组合物和方法
WO2024044557A1 (en) * 2022-08-23 2024-02-29 The Regents Of The University Of California Compositions and methods for targeted delivery of crispr-cas effector polypeptides
WO2024254544A2 (en) * 2023-06-07 2024-12-12 Nvelop Therapeutics, Inc. Compositions and methods for promoting payload delivery in cells
CN121646640A (zh) * 2023-06-16 2026-03-10 胡桃夹子治疗公司 纳米颗粒递送媒介物的比较评估
CN116814566A (zh) * 2023-06-27 2023-09-29 上海交通大学 树突状细胞靶向的类病毒体dvlp及其制备方法和应用
KR20260032590A (ko) * 2023-06-29 2026-03-09 세퀴러스 인코포레이티드 재조합 바이러스 유사 입자
CN117187305B (zh) * 2023-07-26 2024-09-24 山东省农业科学院 斑翅果蝇常染色体基因移码突变纯合品系的构建方法
CN121794285A (zh) * 2023-09-09 2026-04-03 正基基因科技有限公司 工程化蛋白质递送载体
WO2025096936A2 (en) 2023-11-03 2025-05-08 The Broad Institute, Inc. Use of prime editing in correcting mutations in cdkl5
CN117717632B (zh) * 2023-12-13 2024-11-22 深圳市眼科医院(深圳市眼病防治研究所) 利用增强的先导编辑阻断异常血管生成的药剂及制备方法
EP4600357A1 (en) * 2024-02-12 2025-08-13 Technische Universität München Delivery system for gene editing tools
WO2025257403A1 (en) * 2024-06-14 2025-12-18 Dotbio Pte. Ltd. Virus-like particles
CN118497196B (zh) * 2024-07-18 2024-11-01 南方医科大学珠江医院 用于递送siRNA的框架核酸机器及其制备方法与应用
WO2026024856A2 (en) 2024-07-23 2026-01-29 The Broad Institute, Inc. Compositions and methods for production of double-stranded dna in cells for programmable gene integration
WO2026083093A1 (en) * 2024-10-17 2026-04-23 Cambridge Enterprise Limited Virus particles
CN120555402B (zh) * 2025-07-30 2025-10-17 西湖凝聚体(杭州)生物科技有限公司 一种在原代细胞中进行基因编辑的方法

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995031183A1 (en) 1994-05-16 1995-11-23 Washington University Cell membrane fusion composition and method
GB9710809D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
WO1999013905A1 (en) 1997-09-18 1999-03-25 The Trustees Of The University Of Pennsylvania Receptor-binding pocket mutants of influenza a virus hemagglutinin for use in targeted gene delivery
AU746454B2 (en) 1998-03-02 2002-05-02 Massachusetts Institute Of Technology Poly zinc finger proteins with improved linkers
US6534261B1 (en) 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US7013219B2 (en) 1999-01-12 2006-03-14 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US6794136B1 (en) 2000-11-20 2004-09-21 Sangamo Biosciences, Inc. Iterative optimization in the design of binding proteins
US7030215B2 (en) 1999-03-24 2006-04-18 Sangamo Biosciences, Inc. Position dependent recognition of GNN nucleotide triplets by zinc fingers
US20030104526A1 (en) 1999-03-24 2003-06-05 Qiang Liu Position dependent recognition of GNN nucleotide triplets by zinc fingers
CA2392490A1 (en) 1999-11-24 2001-05-31 Mcs Micro Carrier Systems Gmbh Polypeptides comprising multimers of nuclear localization signals or of protein transduction domains and their use for transferring molecules into cells
US20040028687A1 (en) 2002-01-15 2004-02-12 Waelti Ernst Rudolf Methods and compositions for the targeted delivery of therapeutic substances to specific cells and tissues
US20030232410A1 (en) 2002-03-21 2003-12-18 Monika Liljedahl Methods and compositions for using zinc finger endonucleases to enhance homologous recombination
JP2005521398A (ja) 2002-03-27 2005-07-21 ベイラー カレッジ オブ メディスン 癌治療用の強力な腫瘍溶解性単純ヘルペスウイルス
PL377161A1 (pl) 2002-11-21 2006-01-23 Pevion Biotech Ltd. Wysoce efektywne pęcherzyki fuzogenne, sposób ich wytwarzania oraz kompozycje farmaceutyczne zawierające te pęcherzyki
AU2004208031B2 (en) 2003-01-28 2009-10-08 Cellectis Use of meganucleases for inducing homologous recombination ex vivo and in toto in vertebrate somatic tissues and application thereof.
US7842673B2 (en) 2003-12-17 2010-11-30 The Trustees Of Columbia University In The City Of New York Delivery of DNA or RNA via gap junctions from host cells to target cells and a cell-based delivery system for antisense or siRNA
WO2006027202A1 (en) 2004-09-06 2006-03-16 Unite De Recherche En Biotherapie Et Oncologie (Rubio) Generation of multiparent cell hybrids
AU2006224248B2 (en) 2005-03-15 2011-01-06 Cellectis I-Crei meganuclease variants with modified specificity, method of preparation and uses thereof
EP2650366B1 (en) 2005-10-18 2017-03-22 Precision Biosciences Rationally designed meganucleases with altered sequence specificity and DNA-binding affinity
WO2007099387A1 (en) 2006-03-03 2007-09-07 Mymetics Corporation Virosome-like vesicles comprising gp41-derived antigens
JP2009533065A (ja) 2006-04-20 2009-09-17 ジボダン エス エー 味覚物質同定のための機能的方法
US9085778B2 (en) 2006-05-03 2015-07-21 VL27, Inc. Exosome transfer of nucleic acids to cells
US20090203140A1 (en) 2007-09-27 2009-08-13 Sangamo Biosciences, Inc. Genomic editing in zebrafish using zinc finger nucleases
EP2419144B1 (en) 2009-04-17 2019-08-07 Oxford University Innovation Limited Composition for delivery of genetic material
JP5878126B2 (ja) 2009-11-13 2016-03-08 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 工学操作された微小胞を用いての直接的なタンパク質の送達
NO2510096T3 (enExample) 2009-12-10 2015-03-21
EP3608308B1 (en) 2013-03-08 2021-07-21 Novartis AG Lipids and lipid compositions for the delivery of active agents
SG11201508433TA (en) 2013-04-12 2015-11-27 Andaloussi Samir El Therapeutic delivery vesicles
PT3083556T (pt) 2013-12-19 2020-03-05 Novartis Ag Lípidos e composições lipídicas para a entrega de agentes ativos
US20170173113A1 (en) 2014-03-13 2017-06-22 Research Institute At Nationwide Children's Hospital Methods of delivering heparin binding epidermal growth factor using stem cell generated exosomes
IL256175B2 (en) 2015-06-10 2024-10-01 Univ Texas Using exosomes to treat the disease
WO2017068077A1 (en) * 2015-10-20 2017-04-27 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods and products for genetic engineering
US20170112773A1 (en) 2015-10-23 2017-04-27 Board Of Regents, The University Of Texas System Plasma membrane vesicles comprising functional transmembrane proteins
SG10202104041PA (en) 2015-10-23 2021-06-29 Harvard College Nucleobase editors and uses thereof
SI3436077T1 (sl) 2016-03-30 2025-07-31 Intellia Therapeutics, Inc. Formulacije lipidnih nanodelcev za komponente crispr/cas
GB201609216D0 (en) 2016-05-25 2016-07-06 Evox Therapeutics And Isis Innovation Ltd Exosomes comprising therapeutic polypeptides
GB2552301A (en) 2016-07-11 2018-01-24 Evox Therapeutics Ltd Metabolic drug loading of EVs
GB2552460A (en) 2016-07-11 2018-01-31 Evox Therapeutics Ltd CPP-Mediated EV Loading
KR20250103795A (ko) 2016-08-03 2025-07-07 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 아데노신 핵염기 편집제 및 그의 용도
CN110072994A (zh) 2016-12-23 2019-07-30 埃克波菲尔有限公司 用于纯化或分离微泡和外泌体的方法与组合物
GB201702863D0 (en) 2017-02-22 2017-04-05 Evox Therapeutics Ltd Improved loading of EVs with therapeutic proteins
WO2018165629A1 (en) 2017-03-10 2018-09-13 President And Fellows Of Harvard College Cytosine to guanine base editor
WO2018176009A1 (en) 2017-03-23 2018-09-27 President And Fellows Of Harvard College Nucleobase editors comprising nucleic acid programmable dna binding proteins
AU2018316803B2 (en) 2017-08-17 2021-07-15 Ilias Biologics Inc. Exosomes for target specific delivery and methods for preparing and delivering the same
FI3688162T3 (fi) 2017-09-29 2024-05-15 Intellia Therapeutics Inc Formulaatioita
US11795443B2 (en) 2017-10-16 2023-10-24 The Broad Institute, Inc. Uses of adenosine base editors
GB201717446D0 (en) 2017-10-24 2017-12-06 Evox Therapeutics Ltd Affinity purification of engineering extracellular vesicles
AU2018358051B2 (en) 2017-11-01 2025-01-09 The Regents Of The University Of California CasZ compositions and methods of use
US11970719B2 (en) 2017-11-01 2024-04-30 The Regents Of The University Of California Class 2 CRISPR/Cas compositions and methods of use
GB201802163D0 (en) 2018-02-09 2018-03-28 Evox Therapeutics Ltd Compositions for EV storage and formulation
GB201804291D0 (en) 2018-03-16 2018-05-02 Evox Therapeutics Ltd Cell-mediated exosome delivery
KR20250133482A (ko) 2018-05-11 2025-09-05 빔 테라퓨틱스, 인크. 프로그래밍가능한 염기 편집기 시스템을 이용하여 단일 뉴클레오티드 다형성을 편집하는 방법
EP3790964A4 (en) 2018-05-11 2022-06-08 Beam Therapeutics, Inc. METHODS FOR REMOVAL OF PATHOGENIC MUTATIONS USING PROGRAMMABLE BASE EDITOR SYSTEMS
US12157760B2 (en) 2018-05-23 2024-12-03 The Broad Institute, Inc. Base editors and uses thereof
CN112805379B (zh) 2018-08-03 2024-08-20 比姆医疗股份有限公司 多效应核碱基编辑器和使用其修饰核酸靶序列的方法
EP3850088A4 (en) 2018-09-07 2023-07-19 Beam Therapeutics, Inc. Compositions and methods for improving base editing
AU2019336245B2 (en) 2018-09-07 2026-02-26 Beam Therapeutics Inc. Compositions and methods for delivering a nucleobase editing system
US20220380740A1 (en) 2018-10-24 2022-12-01 The Broad Institute, Inc. Constructs for improved hdr-dependent genomic editing
EP3880717A4 (en) * 2018-11-16 2022-11-23 The Regents of The University of California Compositions and methods for delivering crispr/cas effector polypeptides
WO2020160481A1 (en) 2019-02-01 2020-08-06 The General Hospital Corporation Targetable 3'-overhang nuclease fusion proteins
EP3942043A2 (en) 2019-03-19 2022-01-26 The Broad Institute, Inc. Methods and compositions for editing nucleotide sequences
CN114258398A (zh) 2019-06-13 2022-03-29 总医院公司 工程化的人内源性病毒样颗粒及使用其递送至细胞的方法
CN119913134A (zh) 2019-08-29 2025-05-02 比姆医疗股份有限公司 用于编辑突变以允许转录或表达的组合物和方法
AU2020345830A1 (en) 2019-09-09 2022-03-24 Beam Therapeutics Inc. Novel CRISPR enzymes, methods, systems and uses thereof
US12435330B2 (en) 2019-10-10 2025-10-07 The Broad Institute, Inc. Methods and compositions for prime editing RNA
CN121759549A (zh) 2019-12-03 2026-03-31 比姆医疗股份有限公司 合成向导rna、其组合物、方法和用途
BR112022022603A2 (pt) 2020-05-08 2023-01-17 Broad Inst Inc Métodos e composições para edição simultânea de ambas as fitas de sequência alvo de nucleotídeos de fita dupla
US12565647B2 (en) * 2021-05-28 2026-03-03 The Regents Of The University Of California Compositions and methods for targeted delivery of CRISPR-Cas effector polypeptides and transgenes
EP4351660A2 (en) * 2021-06-09 2024-04-17 Scribe Therapeutics Inc. Particle delivery systems

Similar Documents

Publication Publication Date Title
Brouwer et al. Two-component spike nanoparticle vaccine protects macaques from SARS-CoV-2 infection
AU2018241252B2 (en) Chimeric molecules and uses thereof
JP7237960B2 (ja) 標的細胞の選択的形質導入のためのアダプターベースのレトロウイルスベクター系
CN1852734B (zh) 共有/祖先免疫原
ES2877398T5 (en) Retroviral and lentiviral vectors
Paragas et al. Influenza B and C virus NEP (NS2) proteins possess nuclear export activities
Bentley et al. The use of pseudotypes to study viruses, virus sero-epidemiology and vaccination
JP2002522090A (ja) 抗体エンベロープ融合タンパク質および野生型エンベロープタンパク質を含有するレトロウイルスベクターを用いる細胞型特異的遺伝子移入
Kneissl et al. Measles virus glycoprotein-based lentiviral targeting vectors that avoid neutralizing antibodies
Munis et al. Use of heterologous vesiculovirus G proteins circumvents the humoral anti-envelope immunity in lentivector-based in vivo gene delivery
Barnard et al. Alpharetrovirus envelope-receptor interactions
Kowolik et al. Preferential transduction of human hepatocytes with lentiviral vectors pseudotyped by Sendai virus F protein
Ye et al. Induction of HIV neutralizing antibodies against the MPER of the HIV envelope protein by HA/gp41 chimeric protein-based DNA and VLP vaccines
US11400149B2 (en) Ebola virus and Marburg virus glycoprotein mucin-like domain replacement expression system used as new vaccine approaches
US12559527B2 (en) Compositions comprising V2 opt HIV envelopes
Balliet et al. Efficient infection mediated by viral receptors incorporated into retroviral particles
Fisher et al. Oral Immunization with HIV-1 Envelope SOSIP trimers elicits systemic immune responses and cross-reactive anti-V1V2 antibodies in non-human primates
CZ377697A3 (cs) Multifunkční systém ligandů vhodný pro buněčně specifický přenos nukleových kyselin
McKenna et al. Covalently linked human immunodeficiency virus type 1 gp120/gp41 is stably anchored in rhabdovirus particles and exposes critical neutralizing epitopes
Urban et al. Retroviral display in gene therapy, protein engineering, and vaccine development
JP2023550381A5 (enExample)
Stenler et al. Immunization with HIV-1 envelope T20-encoding DNA vaccines elicits cross-clade neutralizing antibody responses
WO2026026977A1 (en) Novel engineered protein delivery vehicles for enhanced delivery
US20110212119A1 (en) Methods for making hiv vaccines and related compositions
RU2697781C2 (ru) Вспомогательный плазмидный лентивирусный экспрессионный вектор для получения высоких титров vpx-содержащих лентивирусных частиц, обеспечивающий эффективное заражение моноцитов и дендритных клеток человека